1-3 of 3
Tracy T. Chow
Close
Sort by
Journal Articles

Preclinical and Translational Biomarker Analyses to Inform Clinical Development of Mezigdomide (CC-92480) in Combination with Dexamethasone and Daratumumab in Multiple Myeloma

Tracy T. Chow, Michael Amatangelo, Peilin Ma, Chad C. Bjorklund, Krista Wollerman, Tiziana Civardi, Phillip Koo, Yue Zhu, Paulo Maciag, Jessica Katz, Aparna Raval, Albert Oriol, Robert Z. Orlowski, Darrell White, Paul G. Richardson, Anita K. Gandhi
Journal: Blood
Blood (2023) 142 (Supplement 1): 3318.
https://doi.org/10.1182/blood-2023-178881
Published: 2023
Journal Articles

Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Daratumumab (DARA) or Elotuzumab (ELO) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the CC-92480-MM-002 Trial

Paul G. Richardson, Irwindeep Sandhu, Craig C. Hofmeister, Robert Z. Orlowski, Darrell White, Angelo Belotti, Charlotte Toftmann Hansen, Noopur S. Raje, Tracy T. Chow, Zehua Zhou, Tiziana Civardi, Phillip Koo, Yue Zhu, Jessica Katz, Albert Oriol
Journal: Blood
Blood (2023) 142 (Supplement 1): 1013.
https://doi.org/10.1182/blood-2023-174443
Published: 2023
Journal Articles

Mezigdomide Treatment in Relapsed-Refractory Myeloma Patients Shifts Bone Marrow NK and T Cell Populations from Exhaustion to Activation

Lucia Y Chen, Oliver Van Oekelen, Michael Amatangelo, Tracy T. Chow, Bhaskar Upadhyaya, Alessandro Lagana, Geoffrey Kelly, Seunghee Kim-Schulze, Adolfo Aleman, Antonina Kurtova, Sarah Gooding, Sundar Jagannath, Erin Flynt, Anita K. Gandhi, Udo Oppermann, Anjan Thakurta, Samir Parekh
Journal: Blood
Blood (2023) 142 (Supplement 1): 4686.
https://doi.org/10.1182/blood-2023-187748
Published: 2023